Max Gelman

John­son & John­son and Pro­tag­o­nist Ther­a­peu­tics an­nounced two Phase 3 suc­cess­es for their oral IL-23 drug, show­cas­ing the first re­sults out of an ex­pan­sive piv­otal

In 2010, neu­ro­sci­en­tist and for­mer Eli Lil­ly re­search leader Steve Paul start­ed a com­pa­ny that he hoped would spark a rev­o­lu­tion in drug dis­cov­ery, built

NEW YORK — As­traZeneca is not back­ing away from Chi­na de­spite an in­ves­ti­ga­tion in­to its pres­i­dent of Chi­na op­er­a­tions. As the com­pa­ny re­port­ed its third-quar­ter

As­traZeneca and Dai­ichi Sankyo are chang­ing the ap­proval sub­mis­sion strat­e­gy for its planned En­her­tu suc­ces­sor, datopotam­ab derux­te­can (Da­to-DXd), af­ter a few missed tri­als. The com­pa­nies

The cen­ter­piece of Ab­b­Vie’s $8.7 bil­lion Cerev­el ac­qui­si­tion just im­plod­ed. Em­r­a­cli­dine, a schiz­o­phre­nia pro­gram ex­pect­ed to com­pete with the new­ly-ap­proved Coben­fy from Bris­tol My­ers Squibb